Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations (vol 110, pg 894, 2014)

被引：2
|
作者：
Hu, S.
Mathijssen, R. H. J.
de Bruijn, P.
Baker, S. D.
Sparreboom, A.
机构：
来源：
BRITISH JOURNAL OF CANCER | 2017年 / 117卷 / 05期
关键词：
D O I：
10.1038/bjc.2017.217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Correction to: British Journal of Cancer (2014) 110, 894–898. doi:10.1038/bjc.2013.811; published online 7 January 2014 After publication of the above paper in the British Journal of Cancer, a discrepancy was found in the text. The Results section contains the following: ‘As a representative of thisclass of TKIs, sorafenib was further evaluated and found to also potently inhibit the OATP1B1-mediated transport of docetaxel with a half-inhibitory maximum concentration of 6.
引用
收藏
页码：e3 / e3
页数：1
相关论文
共 50 条
  • [21] OVERLAP AND DIFFERENCES IN THE INHIBITION OF HUMAN OATP1B1, OATP1B3, MDR1, AND MRP2 BY REGISTERED DRUGS IN VITRO
    Van de Steeg, Evita
    Vlaming, Maria L. H.
    Jansen, Harm T.
    Nooijen, Irene H. G.
    Schrander, Freek L.
    DeGroot, Jeroen
    Wortelboer, Heleen M.
    DRUG METABOLISM REVIEWS, 2012, 44 : 77 - 77
  • [22] In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions
    Karlgren, Maria
    Ahlin, Gustav
    Bergstrom, Christel A. S.
    Svensson, Richard
    Palm, Johan
    Artursson, Per
    PHARMACEUTICAL RESEARCH, 2012, 29 (02) : 411 - 426
  • [23] Evaluating the In Vitro Inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced Hyperbilirubinemia
    Chang, Jae H.
    Plise, Emile
    Cheong, Jonathan
    Ho, Quynh
    Lin, Molly
    MOLECULAR PHARMACEUTICS, 2013, 10 (08) : 3067 - 3075
  • [24] Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
    Roland Heinig
    Robert Fricke
    Sebastian Wertz
    Johannes Nagelschmitz
    Stephanie Loewen
    European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 803 - 815
  • [25] Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions
    McFeely, Savannah J.
    Ritchie, Tasha K.
    Ragueneau-Majlessi, Isabelle
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 47 - 52
  • [26] The application of An OATP1B1 inhibition assay within drug discovery: Use of in vitro and in silico approaches to aid drug design
    Soars, Matt G.
    Barton, Patrick
    Grime, Ken
    Riley, Robert J.
    DRUG METABOLISM REVIEWS, 2009, 41 : 178 - 178
  • [27] Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
    Heinig, Roland
    Fricke, Robert
    Wertz, Sebastian
    Nagelschmitz, Johannes
    Loewen, Stephanie
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (06) : 803 - 815
  • [28] OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture (vol 82, pg 1219, 2011)
    Ulvestad, Maria
    Bjorquist, Petter
    Molden, Espen
    Asberg, Anders
    Andersson, Tommy B.
    BIOCHEMICAL PHARMACOLOGY, 2012, 84 (08) : 1103 - 1103
  • [29] Development of a high-throughput mass spectrometry based analytical method to support an in vitro OATP1B1 inhibition screening assay
    Wagner, Andrew D.
    Elkin, Lisa
    Mosure, Kathy
    Gallagher, Lizbeth
    Stavola, Lindsey K.
    Soars, Matthew G.
    Shou, Wilson
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2016, 30 (15) : 1787 - 1796
  • [30] STATISTICAL ANALYSIS TO COMPARE VARIOUS IN VITRO CRITERIA FOR PREDICTING ORGANIC ANION TRANSPORTING POLYPEPTIDES 1B1 (OATP1B1)-MEDIATED DRUG INTERACTIONS IN VIVO
    Arya, V.
    Vaidyanathan, J.
    Yoshida, K.
    Yang, X.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S21 - S22
12345